All Title Author
Keywords Abstract

PLOS ONE  2012 

α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls

DOI: 10.1371/journal.pone.0052285

Full-Text   Cite this paper   Add to My Lib


α-synuclein is thought to play a key role in Parkinson’s disease (PD) because it is the major protein in Lewy bodies, and because its gene mutations, duplication, and triplication are associated with early-onset PD. There are conflicting reports as to whether serum and plasma concentrations of α-synuclein and anti-α-synuclein antibodies differ between PD and control subjects. The objectives of this study were to compare the levels of α-synuclein and its antibodies between individuals with typical PD (n = 14), atypical Parkinson syndromes (n = 11), idiopathic rapid eye movement sleep behavior disorder (n = 10), and healthy controls (n = 9), to assess the strength of association between these serum proteins, and to determine group sizes needed for a high probability (80% power) of detecting statistical significance for 25% or 50% differences between typical PD and control subjects for these measurements. Analysis of log-transformed data found no statistically significant differences between groups for either α-synuclein or its antibodies. The concentrations of these proteins were weakly correlated (Spearman rho = 0.16). In subjects with typical PD and atypical Parkinson syndromes, anti-α-synuclein antibody levels above 1.5 μg/ml were detected only in subjects with no more than four years of clinical disease. Power analysis indicated that 236 and 73 samples per group would be required for an 80% probability that 25% and 50% differences, respectively, in mean α-synuclein levels between typical PD and control subjects would be statistically significant; for anti-α-synuclein antibodies, 283 and 87 samples per group would be required. Our findings are consistent with those previous studies which suggested that serum concentrations of α-synuclein and its antibodies are not significantly altered in PD.


[1]  Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27: 494–506.
[2]  Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045–2047.
[3]  Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106–108.
[4]  Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167–1169.
[5]  Ibá?ez P, Bonnet AM, Débarges B, Lohmann E, Tison F, et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169–1171.
[6]  Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18: S2–S12.
[7]  Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879–884.
[8]  Sidhu A, Wersinger C, Moussa CE, Vernier P (2004) The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 1035: 250–270.
[9]  Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571–576.
[10]  El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945–1947.
[11]  Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65–67.
[12]  Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, et al. (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75: 1766–1772.
[13]  El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20: 419–425.
[14]  Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55–59.
[15]  Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, et al. (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480: 78–82.
[16]  Lee PH, Lee G, Park HJ, Bang OY, Joo IS, et al. (2006) The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 113: 1435–1439.
[17]  Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, et al. (2007) Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 204: 583–588.
[18]  Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, et al. (2010) Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord 25: 489–493.
[19]  Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-D?ring F, Trenkwalder C, et al. (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230–240.
[20]  Foulds PG, Mitchell JD, Parker A, Turner R, Green G, et al. (2011) Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 25: 4127–4137.
[21]  Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-na?ve patients with Parkinson's disease. J Clin Neurol 7: 215–222.
[22]  Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, et al. (2002) Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 58: 1435–1436.
[23]  Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, et al. (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101: 749–756.
[24]  Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, et al. (2011) Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol 233: 221–227.
[25]  Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, et al. (2011) α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 6: e18513.
[26]  Gruden MA, Yanamandra K, Kucheryanu VG, Bocharova OR, Sherstnev VV, et al. (2012) Correlation between Protective Immunity to α-Synuclein Aggregates, Oxidative Stress and Inflammation. Neuroimmunomodulation 19: 334–342.
[27]  Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46: 388–393.
[28]  Iranzo A (2011) Sleep-wake changes in the premotor stage of Parkinson disease. J Neurol Sci 310: 283–285.
[29]  Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79: 368–376.
[30]  Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson’s Disease. Florham Park: Macmillan. 153–163.
[31]  Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442.
[32]  Patrias LM, Klaver AC, Coffey MP, Loeffler DA (2010) Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. Clin Exp Immunol 161: 527–535.
[33]  SAS Institute (2008) The SAS System for Windows, version 9.2. Cary, NC.
[34]  Hintze J (2011) PASS11. NCSS, LLC, Kaysville, Utah, USA.
[35]  Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, et al. (2011) Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord 31: 413–416.
[36]  Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5: 355–363.
[37]  Smith LM, Klaver AC, Coffey MP, Dang L, Loeffler DA (2012) Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. Int Immunopharmacol 14: 550–557.
[38]  Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, et al. (2011) Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 26: 171–179.
[39]  Woulfe J, Hoogendoorn H, Tarnopolsky M, Mu?oz DG (2000) Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain. Neurology 55: 1398–1401.
[40]  Bartels T, Choi JG, Selkoe DJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477: 107–110.
[41]  Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, et al. (2012) Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J Biol Chem 287: 15345–15364.
[42]  Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857–868.
[43]  Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6: e19338.


comments powered by Disqus